Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Fang, Ping ^a   Hu, Jin hua ^b   Cheng, Zhi gang ^a   Liu, Zhe feng ^a   Wang, Jin liang ^a   Jiao, Shun chang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; GEMCITABINE; OXALIPLATIN; SORAFENIB;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLEEDING; BLOOD TOXICITY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CARDIOVASCULAR DISEASE; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPHAGIA; EDEMA; EPISTAXIS; ESOPHAGUS VARICES; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; INOPERABLE CANCER; LEUKOPENIA; LIVER CELL CARCINOMA; LOWER RESPIRATORY TRACT INFECTION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; RECTUM HEMORRHAGE; RESPIRATORY FAILURE; REVIEW; SEPSIS; SIDE EFFECT; SMALL INTESTINE PERFORATION; STOMACH PERFORATION; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT; WOUND INFECTION; XEROSTOMIA;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LIVER NEOPLASMS; SAFETY; TREATMENT OUTCOME;

EID: 84871294854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049717     Document Type: Review

References (29)

1. Forner A, Llovet JM, Bruix J, (2012) Hepatocellular carcinoma. Lancet 379: 1245-1255.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, et al. (2011) Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 81 Suppl 1: 158-164.
4. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr, (2001) International trends and patterns of primary liver cancer. Int J Cancer 94: 290-296.
5. Thomas MB, Zhu AX, (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23: 2892-2899.
6. Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, et al. (2010) Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol 2: 348-359.
7. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, et al. (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538.
8. Sia D, Villanueva A, (2011) Signaling pathways in hepatocellular carcinoma. Oncology 81 Suppl 1: 18-23.
9. Frenette C, Gish R, (2012) Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications. World J Gastroenterol 18: 498-506.
10. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
11. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
12. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593-4599.
13. Shojaei F, (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320: 130-137.
14. Jain RK, (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
15. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, et al. (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26: 2992-2998.
16. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, et al. (2010) Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 102: 981-986.
17. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, et al. (2011) Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer 117: 3187-3192.
18. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, et al. (2012) Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial. Oncology 82: 67-74.
19. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, et al. (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27: 843-850.
20. Yau T, Wong H, Chan P, Yao TJ, Pang R, et al. (2012) Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs.
21. Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, et al. (2012) Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 118: 2424-2430.
22. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898-1903.
23. Woodburn JR, (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250.
24. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, et al. (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23: 6657-6663.
25. Thomas MB, Chadha R, Glover K, Wang X, Morris J, et al. (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110: 1059-1067.
26. Randall LM, Monk BJ, (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 117: 497-504.
27. Di Fiore F, Van Cutsem E, (2009) Acute and long-term gastrointestinal consequences of chemotherapy. Best Pract Res Clin Gastroenterol 23: 113-124.
28. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
29. Saad ED, Katz A, (2009) Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 20: 460-464.